GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Chemed Corp (NYSE:CHE) » Definitions » EBIT

Chemed (Chemed) EBIT : $366 Mil (TTM As of Mar. 2024)


View and export this data going back to 1982. Start your Free Trial

What is Chemed EBIT?

Chemed's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $366 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chemed's annualized ROC % for the quarter that ended in Mar. 2024 was 16.69%. Chemed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 102.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Chemed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.55%.


Chemed EBIT Historical Data

The historical data trend for Chemed's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemed EBIT Chart

Chemed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 266.14 398.35 352.18 334.26 353.48

Chemed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.72 71.12 93.71 115.94 84.91

Competitive Comparison of Chemed's EBIT

For the Medical Care Facilities subindustry, Chemed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemed's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Chemed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chemed's EV-to-EBIT falls into.



Chemed EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $366 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chemed  (NYSE:CHE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chemed's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=289.332 * ( 1 - 23.04% )/( (1355.185 + 1313.496)/ 2 )
=222.6699072/1334.3405
=16.69 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1668.095 - 124.117 - ( 263.958 - max(0, 312.05 - 500.843+263.958))
=1355.185

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1727.633 - 156.494 - ( 313.35 - max(0, 281.974 - 539.617+313.35))
=1313.496

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Chemed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=339.64/( ( (330.227 + max(-20.83, 0)) + (334.535 + max(-16.428, 0)) )/ 2 )
=339.64/( ( 330.227 + 334.535 )/ 2 )
=339.64/332.381
=102.18 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(181.511 + 12.004 + 43.37) - (124.117 + 0 + 133.598)
=-20.83

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(177.334 + 10.712 + 38.221) - (156.494 + 0 + 86.201)
=-16.428

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Chemed's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=365.669/8033.547
=4.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chemed EBIT Related Terms

Thank you for viewing the detailed overview of Chemed's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemed (Chemed) Business Description

Traded in Other Exchanges
Address
255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative-care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
Executives
Kevin J Mcnamara director, officer: president & ceo 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
Spencer S Lee officer: vice president 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
David Patrick Williams officer: Vice President & CFO
Nicholas Michael Westfall officer: Executive Vice President 8035 PEREGRINE LANE, CINCINNATI OH 45243
Patrick P Grace director 1100 PARK AVE, APT 15C, NEW YORK NY 10128
Eileen P Mccarthy director 3515 78TH STREET, #2, JACKSON HEIGHTS NY 11372
Michael D Witzeman officer: vice president and controller 255 E 5TH STREET, SUITE 2600, CINCINNATI OH 45202
Mount John Meredith Jr. director 2906 MABRY ROAD NE, ATLANTA GA 30319
Donald E Saunders director 306 MIANI TRAIL, OXFORD OH 45056
Christopher J Heaney director 101 S. FORT LAUDERDALE BEACH BLVD., APARTMENT 1602, FORT LAUDERDALE FL 33316
Ron Delyons director 2692 MADISON ROAD, SUITE N1-313, CINCINNATI OH 45208
Naomi C Dallob officer: VP and Chief Legal Officer 255 EAST FIFTH STREET, SUITE 2600, CINCINNATI OH 45202
Thomas C Hutton director, officer: vice president ONE ROCKEFELLER PLAZA, STE 1510, NEW YORK NY 10020
Walsh George J Iii director ONE CHASE MANHATTAN PLAZA, NEW YORK NY 10005
Andrea R Lindell director